Viridian Therapeutics
VRDN
56 hedge funds and large institutions have $44.5M invested in Viridian Therapeutics in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
0.72% more ownership
Funds ownership: 2.45% → 3.17% (+0.72%)
2% less funds holding
Funds holding: 57 → 56 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
37% less capital invested
Capital invested by funds: $71M → $44.5M (-$26.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$6.54M |
| 2 |
Renaissance Technologies
New York
|
+$605K |
| 3 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
+$560K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$508K |
| 5 |
Morgan Stanley
New York
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.66M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.68M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$959K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$946K |
VRDN Hedge Fund Activity: Q4 2018 in Review
56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2018, worth a combined $44.5M — down 37% from $71M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VRDN and 8 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 21 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $6.54M. The largest seller was Opaleye Management, cutting an estimated $3.9M.
- 56 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2018, down from 57 in Q3 2018.
- Funds reported $44.5M of Viridian Therapeutics stock for Q4 2018, down 37% quarter-over-quarter.
- 8 funds opened new Viridian Therapeutics positions in Q4 2018 and 9 closed out, a net change of -1 holder.
- The largest Viridian Therapeutics buyer in Q4 2018 was 683 Capital Management, an estimated $6.54M added.
- The largest Viridian Therapeutics seller in Q4 2018 was Opaleye Management, an estimated $3.9M sold.
Based on aggregated 13F filings for Q4 2018.